Author Archives: Nickholas Bahr

Stockhead – Prominent Perth fundie the main backer in PharmAust’s $3.5m cap raise

MediaBy Nickholas Bahr 13/12/2023

Small Caps – PharmAust adds highly-credentialled members to management team

MediaBy Nickholas Bahr 06/12/2023

Stockhead – Why this ASX biotech is primed to capitalise as big pharma flocks to the rare diseases market

MediaBy Nickholas Bahr 22/11/2023

Appendix 4C and Quarterly Update

Financial Reports 2023By Nickholas Bahr 30/10/2023

Appendix 4E & Full Year Statutory Accounts

Financial Reports 2023By Nickholas Bahr 31/08/2023

The Australian – Results from 11 of 12 patients in PharmAust trial point to stabilised MND progression

MediaBy Nickholas Bahr 24/08/2023

Appendix 4C and Quarterly Update

Financial Reports 2023By Nickholas Bahr 31/07/2023

Appendix 4C and Quarterly Update

Financial Reports 2023By Nickholas Bahr 28/04/2023

Appendix 4D & Half Year Report

Financial Reports 2023By Nickholas Bahr 27/02/2023

Appendix 4C and Quarterly Update

Financial Reports 2023By Nickholas Bahr 31/01/2023